Aenova Appoints CEO and COO

From DCAT Value Chain Insights (VCI)

By People On The Move posted 05-23-2016 12:11


The Aenova Group, a contract development and manufacturing organization, has expanded its management team. The Supervisory Board of the Aenova Holding has appointed Mohammad Naraghi, MD, ScD, to the position of chief executive officer (CEO) effective May 15, 2016. He succeeds to Dr Axel Müller, who had acted as interim CEO since 2015. He will be responsible for strategy, marketing and distribution as well as research and development, communications, quality, and human resources.

Dr Mohammad Naraghi has spent nearly his entire professional life in various international managerial positions in the healthcare and life sciences industry. From 2013 to 2015, he was CEO Germany of the SYNLAB Group, a provider of laboratory services in Europe. He was responsible for business in Germany with approximately 4,500 employees in over 120 medical laboratories, Before he became CEO at SYNLAB, he was with the the New York Head Office of IBM, where he was the Global Leader Healthcare and Life Sciences for the global service business with pharmaceuticals, medtech / biotech and healthcare customers.

In addition, The Supervisory Board appointed Marco Robert Gorgas as the new chief operating officer .He’previously was senior vice president, global operations of the pharmaceuticals producer, STADA Arzneimittel AG. From June 1, 2016, he will be in charge of production and supply chain management.

In addition, Dr Markus Böning retains his position as chief financial officer (CFO) of the Aenova Group, a role he has served since August 2015. His responsibilities include finance, controlling, investor relations, information technology and procurement.

 Source: Aenova 


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription